1. Home
  2. SMID vs TLSI Comparison

SMID vs TLSI Comparison

Compare SMID & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$24.24

Market Cap

157.6M

Sector

Industrials

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.91

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
TLSI
Founded
1960
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.6M
270.2M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
SMID
TLSI
Price
$24.24
$4.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
10.0K
95.6K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
N/A
EPS
0.51
N/A
Revenue
$93,446,000.00
$45,151,000.00
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
$48.02
N/A
Revenue Growth
19.03
53.41
52 Week Low
$23.51
$2.20
52 Week High
$42.15
$7.95

Technical Indicators

Market Signals
Indicator
SMID
TLSI
Relative Strength Index (RSI) 36.02 48.60
Support Level N/A $4.70
Resistance Level $31.47 $5.58
Average True Range (ATR) 1.00 0.28
MACD -0.01 -0.02
Stochastic Oscillator 19.66 43.33

Price Performance

Historical Comparison
SMID
TLSI

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: